Jessica Dunne
Psychiatric/Mental Health · Dubuque, IANPI 1740700632
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 321 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 17.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,580 and has fallen 69.0% since, to $490 in 2025.
Across 321 payments — averaging $13.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$752
- AbbVie$673
- Neurocrine Biosciences, Inc.$557
- Johnson & Johnson$473
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$351
- Otsuka America Pharmaceutical, Inc.$346
- plus $1K from 10 others
What the payments were for
- Food & beverage$4,36498%
- Education$702%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 45 | $752 |
| AbbVie | 40 | $673 |
| Neurocrine Biosciences, Inc. | 69 | $557 |
| Johnson & Johnson | 58 | $473 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 18 | $351 |
| Otsuka America Pharmaceutical, Inc. | 19 | $346 |
| Lundbeck LLC | 16 | $248 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $245 |
| Teva Pharmaceuticals USA, Inc. | 12 | $201 |
| Axsome Therapeutics, Inc. | 7 | $179 |
| Vanda Pharmaceuticals Inc. | 9 | $163 |
| Indivior Inc. | 5 | $104 |
| Sunovion Pharmaceuticals Inc. | 4 | $51 |
| E.r. Squibb & Sons, L.L.C. | 2 | $40 |
| Corium, LLC | 2 | $37 |
| Ironshore Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$116
How this compares
$4,435 in reported general payments places this provider in the 85th percentile of 443 psychiatric/mental health providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 29 | $237,710 |
| Abilify AsimtufiiAripiprazole | 23 | $122,870 |
| Invega SustennaPaliperidone Palmitate | 23 | $76,467 |
| Abilify MaintenaAripiprazole | 22 | $63,932 |
| VraylarCariprazine Hcl | 33 | $47,387 |
| LybalviOlanzapine/Samidorphan Malate | 17 | $29,038 |
| RexultiBrexpiprazole | 17 | $22,638 |
| VivitrolNaltrexone Microspheres | 11 | $17,187 |
| TrintellixVortioxetine Hydrobromide | 32 | $14,518 |
| AuvelityDextromethorphan Hbr/Bupropion | 13 | $14,109 |
| BelsomraSuvorexant | 30 | $13,081 |
| Aripiprazole | 54 | $11,943 |
| VyvanseLisdexamfetamine Dimesylate | 28 | $9,846 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 34 | $6,171 |
| Ramelteon | 33 | $4,819 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $557 | $237,71029 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Asimtufii, Abilify Maintena, Rexulti | $346 | $209,44062 claims |
| Johnson & JohnsonInvega Sustenna | $473 | $76,46723 claims |
| AbbVieVraylar | $673 | $47,38733 claims |
| Alkermes, Inc.Lybalvi, Vivitrol | $752 | $46,22528 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $245 | $24,36460 claims |
| Axsome Therapeutics, Inc.Auvelity | $179 | $14,10913 claims |
| Teva Pharmaceuticals USA, Inc.Loxapine | $201 | $1,32626 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 443 psychiatric/mental health providers in Iowa.
Other psychiatric/mental health in Dubuque
- Mindy RobertsDubuque$6K
- Tracy TschudiDubuque$4K
- Jenni McCannDubuque$4K
- Tarrah HollidayAtlantic$421K
- Kelsie SwisherParkersburg$235K
- Jennifer BradleyCedar Rapids$66K
- Kama AusbornWaterloo$64K
- Quentin ChambersDes Moines$40K
- Tenaea JeppesonFort Dodge$38K
- Jennifer WittmanCoralville$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.